Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.42 |
| ▸ | LATS1 | O95835 | 1/20 | 0.40 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167603 | 1.00 | CRHR1 (0.42) | CRHR1LATS1LATS2KDM4EALDH1A1 | |
| SCHEMBL6166421 | 0.91 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6166430 | 0.81 | CRHR1 (0.38) | CRHR1 | |
| SCHEMBL6345411 | 0.80 | TP53 (0.37) | CRHR1LATS1LATS2ALDH1A1MEN1 | |
| SCHEMBL6350199 | 0.80 | TP53 (0.37) | CRHR1LATS1LATS2ALDH1A1MEN1 | |
| SCHEMBL6168593 | 0.79 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL6167497 | 0.74 | TLR8 (0.40) | CRHR1 | |
| SCHEMBL6166903 | 0.73 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL6169343 | 0.72 | CRHR1 (0.44) | CRHR1LATS1LATS2KDM4EALDH1A1 | |
| SCHEMBL6167585 | 0.72 | CRHR1 (0.44) | CRHR1LATS1LATS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | CRHR1 1/4885LATS1 3708/4885LATS2 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.